In this study, using KRAS(G12D) or PIK3CA(H1047R), two mutations derived from GBM patients, we demonstrated that activation of the RAS/PI3K pathway promotes tumorigenesis and necrosis formation. Here, PIK3CA is linked to glioblastoma.